Advanced Urothelial Carcinoma
Advertisement
Membranous NECTIN-4 expression is frequently decreased or absent altogether in metastatic urothelial carcinoma tissue.
After five years follow-up, new results show the durability of response to pembrolizumab for metastatic urothelial carcinoma.
A newly published case report may signify a promising novel antitumor strategy in locally advanced or metastatic UC.
Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma.
Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy.
FGFR-directed therapy had similar efficacy to chemotherapy in treating advanced or metastatic urothelial carcinoma.
Enfortumab vedotin ranks first in efficacy among 6 treatments for metastatic urothelial cancer.
Shilpa Gupta, MD, discusses treatments for cisplatin-ineligible patients with advanced bladder cancer.
Women with advanced urothelial carcinoma have a significantly greater risk of progression after chemotherapy than men.
Lymphovascular invasion in upper tract urothelial carcinoma puts patients at higher risk for recurrence and mortality.
The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.
Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.
Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.
Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.